|
MRUS | Merus N.v. |
|
|
MRUS | Merus N.v. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.14 |
| Leverage | 14.30% |
| Market Cap | $ 5.6B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -380.8m |
| Margin | -756.73% |
Merus NV, a clinical-stage immuno-oncology company, is dedicated to the discovery and development of bispecific antibody therapies in the Netherlands. The company is headquartered in Utrecht, the Netherlands.